Consortium Biospecimen Program


To develop a comprehensive biological specimen collection and distribution system to facilitate cancer research across Washington

Anticipated Impact: 

More effective cancer therapies and improved tests for early diagnosis and prediction of treatment responses


Development of molecular tests for early diagnosis of cancer and other diseases, as well as tests that enable treatments to be tailored to a patient's condition and new therapeutic technologies, are critically dependent on blood and tissue samples collected from patients and healthy individuals with their consent. To catalyze the development of new diagnostic tests and drugs, the investigators will develop an information-rich biospecimen collection and distribution system that links regional biomedical investigators with biological specimens. A cross-institution informatics platform will be developed, as well as standardized practices for materials transfer and intellectual property management. This new program will capitalize on the resources and expertise of two programs previously funded by LSDF, the Phase 1 Clinical Trials Program and the Northwest Institute of Genetic Medicine. The CBP represents a collaboration between patients and researchers that provides an opportunity for cancer patients, their families, and friends to contribute to basic science and exciting discoveries that may one day lead to cures.

Collaborating organization: Microsoft

See also:

Cancer Diagnostics, Therapeutics

Grant Update

Principal Investigator:
Peggy Porter
Grantee Organization:
Fred Hutchinson Cancer Research Center
Grant Title:
Consortium Biospecimen Program (CBP)
Grant Cohort and Year:
2009 Program Grant (02)
Grant Period:
09/02/2010 - 09/01/2013 (Completed)
Grant Amount:
The major medical advances in this country, including development of the targeted cancer therapies and cancer screening and diagnostic markers, have been realized by research access to human biospecimens. Our program, now named NWBioTrust (, encompasses research at the Fred Hutchinson Cancer Research Center, the University of Washington and Seattle Children’s Hospital. Through the generous funding from LSDF, the NWBT has built a collection and distribution system that provides reliable, convenient access to well-characterized biospecimens, from an informed, engaged patient population, in a manner that is cost-effective and sustainable. Funding over the three years, has allowed us to meet our goal; we have operationalized collection and distribution systems at each of the participating institutions and providing cancer researchers with the means to develop novel technologies that will improve disease detection and treatment. Our next steps are to integrate the biospecimen resources with complementary initiatives aimed at providing Precision Medicine to citizens of Washington State. We are encouraged by the support and interest from researchers in our institutions and throughout the region as we launch this exciting resource.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46, 48

Health Impacts

Cancer Diagnostics, Therapeutics

Oct 3, 2011
Fred Hutchinson Cancer Research Center News